Author

F. Nimmerjahn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Lux· 3 shared A. S. Meyer· 2 shared M. Biburger· 2 shared S. Fischer· 2 shared A. Cagigi· 1 shared A. Carle· 1 shared A. E. H. Bentlage· 1 shared A. R. Cruz· 1 shared

Activity by Year

2017-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Lux

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Macrophages foster adaptive anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction

K. Fuchs, I. Armstark, R. van Roey, Y. Hajjaj, E. D`Avanzo, R. Liguori, F. Ferrazzi, J. Ackermann, L. Amon, M. Alfredo, M. Faas, J. Huebner, M. H. Hoffmann, G. Kroenke, C. Becker, , H. Schuhwerk

This study identifies ZEB1 as a key regulator of TAM-mediated T cell trafficking, enhancing CTL recruitment and immunosurveillance in tumors and metastases.

bioRxiv · Feb 26, 2024Cancer Biology

Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates

Z. C. Tan, A. Lux, M. Biburger, P. Varghese, S. Lees, F. Nimmerjahn, A. S. Meyer

This study examines how mixed Fc domain immune complexes bind Fc receptors, showing blended binding profiles and refined affinity estimates for low-affinity interactions.

Cell Reports · Jul 1, 2023Peer-reviewedImmunology

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor independent agonistic anti-CD40 antibody in rhesus macaques

X. Yan, S. Ols, R. Arcoverde Cerveira, K. Lenart, F. Hellgren, K. Ye, A. Cagigi, M. Buggert, F. Nimmerjahn, J. Falkesgaard Hojen, D. Parera, U. Pessara, S. Fischer, K. Lore

This study introduces an Fcγ-receptor independent agonistic anti-CD40 antibody that activates immune cells in vitro and in vivo in rhesus macaques, showing potential as an immunostimulatory adjuvant.

bioRxiv · Mar 22, 2023Immunology

Fcgamma-receptor-independent controlled activation of CD40 canonical signaling by novel therpeutic antibodies for cancer therapy

C. Reitinger, K. Beckmann, A. Carle, E. Bluemle, N. Jurkschat, C. Paulmann, S. Prassl, L. Kazandijan, F. Nimmerjahn, S. Fischer

Novel Fc-silenced anti-CD40 antibodies activate antigen-presenting cells and humanized mice without Fcγ-receptor dependence, showing efficacy and reduced toxicity compared to existing therapies.

bioRxiv · Jan 16, 2023 · PreprintImmunology

Staphylococcal protein A inhibits IgG-mediated phagocytosis by blocking the interaction of IgGs with FcγRs and FcRn

A. R. Cruz, A. E. H. Bentlage, R. Blonk, C. J. C. d. Haas, P. C. Aerts, L. M. Scheepmaker, I. G. Bouwmeester, A. Lux, J. A. G. v. Strijp, F. Nimmerjahn, K. P. M. v. Kessel, G. Vidarsson, S. H. M. Rooijakkers

bioRxiv · Jan 21, 2022 · PreprintMicrobiology

Dissecting FcγR Regulation Through a Multivalent Binding Model

R. A. Robinett, N. Guan, A. Lux, M. Biburger, F. Nimmerjahn, A. S. Meyer

This paper develops a multivalent binding model to predict FcγR-immune complex interactions and enables rational design of immune complexes for desired effector functions.

bioRxiv · Nov 27, 2017Immunology